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Current Approaches to Drug Therapy for the Hypercholesterolemic Patient Joseph L. Witztum, MD Although atherosclerosis is a multifactorial disease, it is nevertheless clear now that cholesterol plays a central role in the atherogenic process. In fact, it is the extensive intimal deposition of cholesterol that characterizes early and advanced atherosclerotic lesions. Circulating plasma lipoproteins, chiefly low-density lipoproteins (LDL), are believed to be the exclusive source of the cholesterol that is deposited within intimal cells and in the extracellular space of the artery wall.1 Undoubtedly, many factors can initiate or contribute to the atherogenic process. Nevertheless, irrespective of what the primary event is that leads to initiation of atherosclerosis in any given individual, atherosclerosis cannot be sustained or become clinically significant without elevated LDL cholesterol levels. Some individuals with elevated cholesterol levels could remain free of significant coronary artery disease (CAD) if they lack other risk factors. In fact, among individuals with familial hypercholesterolemia (FH), who have had a lifetime of sustained elevation of LDL levels, there is also great diversity in the expression of CAD, even in individuals with very closely matched plasma cholesterol levels.2 Conversely, even in the presence of other risk factors, symptomatic CAD usually does not occur in the absence of hypercholesterolemia. The fact that Japanese males have the lowest incidence of CAD among Western populations, despite a high prevalence of smoking and hypertension, perhaps best illustrates the concept that low levels of plasma cholesterol are protective. The chief concept that must be understood, however, is that "hypercholesterolemia" probably refers to any plasma total cholesterol level above 180 mg/dl. Levels below this value characterize the plasma cholesterol levels found in Japanese populations. Contrast this to the plasma cholesterol levels of adult Americans, for example, which usu-ally exceed 200 mg/dl, and one can readily understand that a large fraction of the American population is indeed hypercholesterolemic. It is not surprising that in the context of a high prevalence of other risk factors (e.g., smoking), these modest degrees of hypercholesterolemia lead to atherosclerosis and symptomatic CAD.
Control of Plasma LDL Levels
Because any total plasma cholesterol level above 180 mg/dl represents hypercholesterolemia and amplifies other known (and still undefined) CAD risk factors, plasma cholesterol levels become a dominant factor in determining the development of atherosclerosis in our population. Therefore, it is important to understand what controls cholesterol levels and, in particular, plasma LDL levels. In the fasting state, the liver is the chief source of circulating lipids (Figure 1 ). The liver synthesizes apolipoprotein B, cholesterol, and triglycerides and secretes these as lipoproteins, known as the very low-density lipoproteins (VLDL), which are triglyceride enriched. As the particles circulate, triglycerides are removed by the action of the enzyme lipoprotein lipase, which generates remnant particles, known as the intermediate-density lipoproteins (IDL). These particles either return to the liver, where they are taken up by receptor-mediated processes, or are converted to mature LDL particles. The plasma concentrations of LDL, and possibly IDL, primarily mediate the atherogenicity of plasma cholesterol.
Our knowledge of the factors that control LDL levels has been greatly enhanced by a long series of elegant studies conducted by Brown, Goldstein, and colleagues. These investigators discovered the fundamental processes regulating LDL levels in humans and animals.3 They showed that on the surface of all normal human cells exists a specialized protein, the LDL receptor, that binds the apolipoprotein B on LDL particles with high affinity, and this leads to the internalization of the LDL particle through a highly regulated process known as the LDL receptor pathway. As shown in the right side of Figure 1 , when LDL particles are exposed to fibroblasts, in vivo, or for example, in tissue culture, the LDL particles first bind to the LDL degraded, and CE is converted to free cholesterol. The fr-ee cholesterol then mediates a variety of cellular regulatory functions as explained in the text. The LDL receptor pathway was modified from Figure 4 of Reference 3, with permission.
receptor on the surface of the cell. Subsequently, the receptor and the LDL particle are internalized and delivered to an intracellular organelle, a lysosome. Here, the LDL particle is released from its receptor, and the receptor then recycles to the surface of the cell. Within the lysosome, the protein component of the LDL is degraded, but the cholesterol is converted to a free form that leaves the lysosome and is then used by the cell for various cellular processes, including new cell membrane synthesis, hormone synthesis (e.g., in the adrenal gland), or for reesterification to be stored as a cholesterol ester droplet. Internalization of LDL by means of this receptor pathway leads to downregulation of cellular LDL receptors when sufficient cholesterol has accumulated within the cell. In addition, the internalized cholesterol inhibits the cell's own cholesterol synthetic pathway. This efficient regulatory pathway thus provides the cell with sufficient cholesterol for its physiologic needs, but it prevents the overaccumulation of free or cholesteryl esters, which could be toxic to the cell. It should be noted that in cell culture experiments, the amount of LDL cholesterol needed to ensure such cellular cholesterol homeostasis is only 2.5 mg/dl. If these in vitro cell culture conditions are repre-sentative of the situation in vivo and if the fibroblast is representative of peripheral cells in the body, then the conditions would imply that the extracellular fluid bathing such cells needs to contain only 2.5 mg/dl of LDL cholesterol. Because a concentration gradient of 10 to 1 exists for LDL between plasma and extracellular fluid, this implies that only 25 mg/dl of circulating LDL cholesterol is needed in plasma to supply the physiologic needs of the human body! If the plasma LDL cholesterol levels are inspected for a variety of mammalian species known to be resistant to spontaneous development of atherosclerosis, their LDL cholesterol levels, on average, are found to range from 25 to 40 mg/dl.4 Even newborn human infants have LDL cholesterol levels in this range, and only later in life do the "normal" LDL cholesterol levels of 125 to 130 mg/dl develop. Although it is unclear what combinations of environmental, developmental, and hormonal factors lead adults to acquire such an elevated plasma level of LDL, it is nevertheless clear that even such '"normal" human levels are far in excess of bodily needs. A dramatic example of this can be found in the report of Young and colleagues5 who recently described a family with hypobetalipoproteinemia in 18 which the proband was a 71-year old healthy male with an average LDL cholesterol level of 5 mg/dl. Other affected hypocholesterolemic family members were also healthy and long lived. Although I am not advocating therapeutic measures to decrease plasma levels this low, nevertheless it is reasonable to conclude that LDL cholesterol levels above 100 mg/dl (and total plasma cholesterol levels above 180 mg/dl) truly represent "hypercholesterolemia" from a physiologic point of view.
In the American population, cardiovascular disease increases directly in relation to increasing total plasma cholesterol levels above 180 mg/dl. Support for this concept within the American male population is found in the results of a prospective study of 360,000 men recently reported from the Multiple Risk Factor Intervention Trial (MRFIT).6 This study documented that morbidity and mortality from cardiovascular disease increased proportionally above a total plasma cholesterol level of 180 mg/dl ( Figure  2 ). For example, in men without any other risk factors, the risk of death from CAD during a 6-year period was increased nearly 50% for those with an initial plasma cholesterol level of 180-200 mg/dl compared with those with levels less than 180 mg/dl (Table 1) and was increased fourfold for men with cholesterol levels greater than 245 mg/dl. In men who have other major risk factors, such as hypertension and smoking, the risk is even greater. For example, a hypertensive smoker with a plasma cholesterol level of only 200-220 mg/dl nevertheless has a nearly 10-fold greater risk than a normotensive nonsmoker with plasma cholesterol levels less than 180 mg/dl (Table 1) . LDL receptors are found on nearly all mammalian cells, and in normal humans, the LDL receptor pathway is responsible for clearance of up to 75% of LDL particles from blood.7 The highest concentration of such receptors is found on steroidogenic tissues, such as the adrenal gland, but the bulk of such receptors are found in the liver.3,8 Thus, the hepatic LDL receptor activity is chiefly responsible for maintaining LDL levels in humans and animals and accounts for 60% or more of the removal of LDL particles from blood.8 When the activity of such receptors is reduced, LDL particles accumulate in plasma, and atherosclerosis could ensue.
Understanding the factors that control and regulate LDL receptor activity is crucial in understanding what controls plasma LDL levels. A number of hormonal factors, such as estrogens, insulin, and thyroid hormone are necessary for maximal expression of LDL receptor activity, whereas certain dietary components, such as cholesterol itself and saturated fat appear to down-regulate hepatic LDL receptor activity.3 Brown, Goldstein, and colleagues have cloned the LDL receptor and have determined in detail the structure of the protein and the sequence of the genomic DNA. Fundamental knowledge elucidating the mechanisms regulating gene transcription (and translation) can be expected in the near future that will undoubtedly guide future therapeutic efforts in regulating LDL receptor activity.
It has long been recognized that severe hypercholesterolemia runs in families and that the mode of inheritance of the hypercholesterolemic trait is autosomal dominant. Brown, Goldstein, and colleagues showed that the fundamental defect in such patients was a genetic alteration or deletion in the LDL receptor gene leading to functional deficiencies or absence of the LDL receptor on the surface of cells. [2] [3] [4] The presence of one abnormal gene meant that the liver, for example, could only maximally express half the number of normal LDL receptors and, therefore, could remove LDL from plasma only 50% as efficiently as would occur in normal individuals. Such heterozygous patients typically have LDL levels twice normal. In rare individuals, who are homozygous for a deficiency of the LDL receptor gene, there are no functional LDL receptors, and hence, plasma cholesterol levels are greatly elevated, even achieving values over 1,000 mg/dl. Individuals who are heterozygous for LDL receptor deficiency are at greatly increased risk for CAD because they have a lifetime of sustained elevations of plasma LDL levels, which can then interact with other risk factors. Thus, approximately 50% of affected men from selected families reportedly have some manifestation of cardiovascular disease by age 60.9 (Parenthetically, it might be noted that 50% remain disease free at this age despite hypercholesterolemia, which also shows the importance of the other risk factors or "protective" factors.) The homozygote patients with greatly elevated plasma cholesterol levels, typically have severe CAD in the 1st decade of life and even as early as the 1st year. 2 The central role of the hepatic LDL receptor activity in maintaining normal plasma cholesterol levels has been most dramatically shown in such a homozygote patient, who underwent a combined liver-heart transplantation.10 In this young girl, plasma cholesterol levels exceeded 1,000 mg/dl before liver transplantation, but after receipt of a normal liver, with a normal complement of hepatic LDL receptors, her plasma cholesterol level promptly fell approximately 70%.
As noted above, Brown, Goldstein, and colleagues have determined the structure of the LDL receptor and have traced the steps involved in the synthesis of this vital cellular protein. To date, many different genetic defects along the LDL receptor pathway have been described,3 and their exact molecular defect has been defined. It is hoped that as the molecular basis for hypercholesterolemia continues to be defined in individual patients, particularly in patients with homozygous disease, and as advances in "gene therapy" continue, we might anticipate genetic correction of their defects. Already investigators are learning how to insert functional LDL receptors into deficient cells by using a viral vector to introduce a normal gene. For example, studies in La Jolla, California, have shown that it is possible to convert fibroblasts that completely lack functional receptors into "normal" fibroblasts by introducing a normal LDL receptor gene into the cell through a retroviral vector.1" Wilson and col-leagues12 have achieved similar results in hepatocytes. Some day, such therapeutic efforts could obviate the need for drug therapy, but obviously, much remains to be learned before such techniques can be accomplished. For the present, we must rely on our ability to manipulate the LDL receptor by dietary and pharmacologic means to achieve desirable plasma LDL levels.
Regulation of LDL Receptor Activity by
Drug Therapy Knowledge of the physiologic mechanisms of lipoprotein receptor expression is now used to develop optimal strategies of therapy. Because LDL receptor plays such a dominant role in regulating plasma cholesterol levels, maximal expression of hepatic LDL receptor activity will probably lead to lower plasma LDL levels and should be a goal of therapy. Such therapy will be effective for individuals with normal alleles for the LDL receptor; even individuals who have only one normal allele (FH heterozygotes) will benefit because in the absence of therapy these individuals do not fully express their capacity to make LDL receptors.
Thus, maintenance of a diet low in dietary cholesterol and low in saturated fat leads to "upregulation" of hepatic LDL receptor activity and lowered plasma cholesterol levels.3 Regulation of LDL receptor activity also appears to underlie the mechanisms by which many commonly used hypolipidemic drugs affect plasma cholesterol levels. As a corollary, the homozygous patient who is incapable of expressing any degree of LDL receptor activity will not respond to those changes or to most hypolipidemic drugs. Consequently, nonpharmacologic and rather heroic measures, such as continued plasmapheresis or even hepatic transplantation, must be used. As shown in Figure 3 , the hepatocyte is the primary site of cholesterol synthesis in the human body. The cholesterol made by this cell is excreted into plasma in the form of lipoproteins or is converted to bile acids by enzymatic modification. Bile acids are then stored in the gall bladder and released into the intestine to facilitate fat absorption. Over 95% of all bile acid molecules are reabsorbed and recycled through the liver up to seven times per day. The bile acid-binding resins work by binding bile acids in the intestine and preventing the reabsorption of a significant fraction. Very likely, the soluble dietary fibers, such as oat bran, lower plasma cholesterol in a similar manner. In response to bile acid depletion, the hepatocyte actually increases cholesterol (and triglyceride) synthesis. This is apparently not sufficient to compensate for depletion of some intracellular sterol metabolite, and the hepatocyte responds by increasing LDL receptor expression, which consequently directly removes LDL particles (or their precursors) from blood.3"13 In this way, a nonsystemic agent leads to enhanced removal of plasma LDL particles, lowered plasma cholesterol levels, and decreased risk for CAD.14 However, the enhanced cholesterol (and triglyceride) synthesis could negate, in part, the cholesterol-lowering effect by leading to enhanced release of cholesterol-carrying lipoproteins (e.g., VLDL) into the plasma (Figure 1 ). This is undoubtedly why many patients develop a transient or even permanent elevation of plasma triglycerides (VLDL) in response to a bile sequestrant even as LDL levels are lowered.15 Furthermore, in some patients, the enhanced production partially offsets the enhanced LDL removal, leading to suboptimal lowering of LDL levels. For these reasons, a second agent, in combination with the bile sequestrant, is frequently used and leads to synergistic lowering of LDL levels. Thus, nicotinic acid, which effectively inhibits release of lipoproteins from the liver, is quite efficacious when combined with a bile acid-binding resin. [16] [17] [18] [19] Even more dramatic is the use of an HMG CoA (3-hydroxy-3-methylglutaryl Coenzyme A) reductase inhibitor, such as lovastatin, which specifically inhibits the rate-limiting step of cholesterol biosynthesis.20 Lovastatin directly inhibits cholesterol synthesis, and thus, not only inhibits the production of new lipoproteins, but by efficiently depleting still further specific hepatic cholesterol pools, lovastatin leads to maximal expression of hepatic LDL receptor activity when used in conjunction with the bile acid-binding resins.21 As noted in detail later, the combination of a bile sequestrant and an HMG CoA reductase inhibitor can produce lowering of LDL levels of greater than 50%,22-25 whereas the combination of three agents, a bile sequestrant, an HMG CoA reductase inhibitor, and nicotinic acid can act synergistically to lower LDL levels by as much as 70%. 26 Of course, many other factors also affect LDL levels, including the activity of lipoprotein lipase and other factors that affect the hepatic production of lipoproteins ( Figure 1 ). Genetic, hormonal, and environmental factors, such as diet, that affect lipoprotein lipase levels and activity, as well as factors that affect hepatic lipoprotein production, have not yet been carefully defined, but these factors also will probably be important for many individuals. Further research is clearly warranted in these important areas. However, at an operational level, for the vast majority of patients, it is the activity of LDL receptors, principally in the liver, that determines plasma LDL levels. Consequently, in large part, current therapeutic strategies are aimed at increasing hepatic LDL receptor activity. As an increased understanding evolves of the genetic and physiologic control of these receptors, even more efficient therapy for the hypercholesterolemic patient can be expected.
Mechanism by Which Elevated LDL
Causes Atherosclerosis Finally, before dealing with the practical problems of whom to treat and how, we should address the issue of how elevated plasma concentrations of LDL lead to the development of the atherosclerotic plaque. Although much remains to be learned, recent advances in our understanding of the cellular mechanisms leading to enhanced uptake of LDL into arterial wall cells promises the potential for new therapeutic interventions in this area as well. Recent evidence strongly supports the concept that one of the earliest events in the development of the fatty streak is the recruitment of circulating monocytes into the intima of the arterial wall.' Once within the intima, such cells phenotypically change to become macrophages. Paradoxically, macrophages do not appear to take up LDL very efficiently, and in fact, in cell cultures, LDL cannot convert macrophages to the foam cells that typify the early atherosclerotic lesion. How then does LDL cause macrophages to become foam cells? This paradox was solved by the suggestion, first advanced by Brown, Goldstein, and colleagues,27 that macrophages take up modified forms of LDL. The natural function of the macrophage is to remove foreign or damaged proteins. A variety of postsecretory modifications of LDL have been produced in vitro that can cause the modified LDL to induce foam cell formation in macrophages (reviewed in Reference 28). These modifications include peroxidation of LDL lipids, complex formation with other macromolecules, such as immunoglobulins, and chemical modification, such as the nonenzymatic glycation that occurs in the presence of hyperglycemia. This scheme suggests that LDL derives much of its atherogenicity by becoming modified and, hence, has accelerated uptake into macrophages that results in the formation of foam cells. This scheme also implies that if one could interfere with the modification, then one should be able to inhibit or retard atherogenesis independent of efforts to lower LDL levels. Recent data from our laboratory document that a hypolipidemic agent, probucol, is also a potent lipophilic antioxidant and that at the usual therapeutic doses it can confer on LDL protection against in vitro induced oxidative damage. 29 More important, when given to hypercholesterolemic rabbits, probucol greatly retarded the development of atherosclerosis, even though it failed to significantly lower plasma LDL levels.30 These exciting, though preliminary, studies support future research aimed at inhibiting oxidative modification of LDL. If such measures prove useful in humans as well, therapeutic efforts will surely be directed not only at measures to lower LDL levels (as discussed below) but also at measures designed to inhibit the pertinent biologic modifications of LDL that increase its atherogenicity.
Such efforts, when combined, could yield highly effec-tive therapy aimed at preventing, or even inducing, regression of the atherosclerotic process.
Whom to Treat
The discussion above has developed the theoretical argument that hypercholesterolemia may be viewed as the presence of any plasma cholesterol level above 180 mg/dl. Obviously, the vast majority of Americans have cholesterol levels above the ideal. Consequently, there is an intensive ongoing attempt to educate the general public as to appropriate dietary guidelines to achieve lower plasma cholesterol levels. The Expert Panel of the National Cholesterol Education Program has recommended specific desirable blood cholesterol levels for the population as a whole.31 Thus, total cholesterol levels are classified as follows: less than 200 mg/dl, desirable blood cholesterol levels; 200-239 mg/dl, borderline high blood cholesterol levels; greater than 240 mg/dl, high blood cholesterol levels. Corresponding LDL cholesterol levels are less than 130 mg/dl, desirable; 130-159 mg/dl, borderline; greater than 160 mg/dl, high-risk LDL cholesterol levels. Although these cutoff points are appropriate for consideration of the population as a whole, assessment of the appropriate cholesterol level for the individual patient must be performed in the context of the presence of other risk factors. Although individuals with very high plasma cholesterol levels clearly are at increased risk for CAD, nevertheless, most patients who develop CAD have total and LDL cholesterol levels that would place them in the "borderline" risk category. For example, in a recent survey of 150 consecutive patients found to have CAD by coronary angiography, the average plasma cholesterol level was only 199 mg/dl (S.G. Young, R. Smith, and J.L. Witztum, unpublished observations). As noted in the introduction of this paper, even among FH patients, there is diversity in the expression of CAD. Thus, individuals with hypertension, smoking history, obesity, or diabetes are clearly at increased risk. Individuals with low levels of high-density lipoprotein (HDL) cholesterol (i.e., <35 mg/dl) are also at risk. In addition, clinical evidence suggests that a strong family history of heart disease is highly predictive of those individuals who are at increased risk. Finally, for patients who have existing CAD, and in particular those who have already undergone coronary artery bypass graft (CABG) surgery, the cholesterol levels listed above are probably too high, and any total plasma cholesterol level above the ideal of 180 mg/dl (corresponding to an LDL cholesterol level of approximately 100 mg/dl) is likely to be too high. Thus, for the high-risk patient frequently encountered by the cardiologist, that is, the FH patient with a strong family history of CAD, or an individual with existing CAD, or a patient after undergoing CABG ideal lipoprotein levels should be the goal of therapy. Regression studies in hypercholesterolemic primates show that the extent of regression of arterial lesions is directly proportional to the extent of cholesterol lowering. 32 The Lipid Research Clinics Primary Prevention Trial also showed that those individuals who achieved the greatest reduction in plasma cholesterol levels were the same individuals who had the greatest beneficial effects.14 In fact, a number of prospective clinical trials have now clearly documented that lowering total plasma cholesterol levels will prevent the development of CAD (reviewed in References 14, 33, and 34) . In general, these studies show that for each 1% lowering of total plasma cholesterol, there is a 2% reduction in coronary events during the next few years. The prospective Helsinki Heart Study recently reported a substantial reduction in CAD by using a drug that lowered triglycerides (VLDL) and cholesterol (LDL) and also raised HDL levels. 35, 36 Finally, Blankenhorn et al37 showed that lowering total plasma cholesterol levels to 165 mg/dl in subjects after CABG led to substantial inhibition of the progression of CAD, even in individuals whose baseline cholesterol levels were only 216 mg/dl. Thus, the maximal beneficial effect seems to come from maximal cholesterol lowering.
In practical terms, an LDL cholesterol level of 130 mg/dl or less should be the goal of treatment for most subjects with hypercholesterolemia.31 I also suggest that for the high-risk subject, an LDL cholesterol level of less than 100 mg/dl should be the ideal goal of therapy. This latter category includes adult patients with heterozygous FH who also have a family history of early CAD and have other risk factors. It includes other hypercholesterolemic patients with LDL cholesterol levels exceeding 200 mg/dl and other risk factors. This category also includes patients who already have existing CAD or who have undergone CABG. It also includes other patients with multiple CAD risk factors, including low HDL levels. Goals for different patients are summarized in Tabla 2.
For the patient with mild hypercholesterolemia, diet alone may be sufficient to achieve the desired goal. For many others, the use of diet plus one hypolipidemic agent will be sufficient. However, for some patients, particularly those with FH, who usually have LDL cholesterol levels in excess of 200 mg/dl, therapy needs to lower LDL levels by 50% or more. 38 Although occasional patients may have 50% drops in LDL levels in response to a single hypolipidemic agent, it is far more common to see decreases of only 20-35%. Thus, under ideal conditions, the bile sequestrants produce drops in LDL of 25-35%; nicotinic acid (in the estimated 60% of patients who can tolerate the required high doses) produces decreases of 20-35%; probucol produces decreases of 15-40% in responding patients (but many patients do not respond), and lovastatin, at doses of 20-80 mg/day, will cause decreases of 35-45%. Thus, for most individuals with heterozygous FH, or severe hypercholesterolemia, a combination of two or occasionally even three medica- (Table 3) .
Individual available medications are described below, along with their indicated uses, followed by an integrated plan presented for the treatment of the hypercholesterolemic patient. Drugs commonly used to lower elevated LDL levels include the bile acid sequestering resins (such as cholestyramine and colestipol hydrochloride), nicotinic acid, and the new and powerful HMG CoA reductase inhibitors (such as lovastatin). Probucol and the fibratelike derivatives, such as gemfibrozil, are also used as adjunct therapy, usually in combination with other medication. Dosages and typical costs of commonly used hypolipidemic agents are summarized in Table 4 .
Drugs Commonly Used to Lower Elevated Levels of LDL Cholesterol Bile Acid Sequestering Agents
Cholestyramine and colestipol are the current drugs of choice for lowering LDL levels. These drugs are nonabsorbable anion exchange resins that are hydrophilic but insoluble in water. They bind bile acids in the intestinal lumen and prevent their reabsorption in the terminal ileum. As explained above, this leads to increased expression of hepatic LDL receptors and consequent lowering of plasma LDL levels. Because these agents require functioning hepatic LDL receptors, they are ineffective in individuals who genetically lack LDL receptors such as those with homozygous FH. However, they 43 Prices were based on costs to the patient at a large discount pharmacy. Prices vary considerably between pharmacies. *Prices are for bulk form; individual packets are far more expensive.
tTypical costs for purchase of nicotinic acid over the counter.
are effective in most patients with heterozygous FH because even their one normal gene is not fully expressed.
The successful use of these drugs requires a "positive attitude" by the prescribing physician, and attention to medication compliance is vital in motivating patients to take these drugs. Both preparations are available in packets and bulk form, and the latter should be prescribed whenever possible because it is far less expensive. Recently, cholestyramine became available in the form of a candy bar, which could be preferable to some patients. Patients should be instructed to take the medication within half an hour of a meal, either shortly before or after, and preferably with the largest meal of the day. I usually have my patients start with only one scoop in a glass of water (or other liquid) at one meal daily, preferably supper, for 1 week and then gradually increase the amount consumed to a maximal dose of four to six scoops per day. Some patients experience bloating, or even nausea, on the small initial dose, but if the medication is continued, these side effects almost always disappear. By increasing fluid intake and by taking medication on a regular basis, side effects are decreased. The medications are palatable in cold water but can be mixed with a variety of liquids according to the patient's preference. Constipation, which is an occasional side effect, can usually be managed by increased water intake, increased intake of bran, or the occasional use of stool softeners. Because these agents are anion exchange resins, they could bind certain medications given concurrently, such as thyroid hormone, but this can be avoided by giving such medications at least 1 hour before the administration of the bile resins.
In some patients, mild or even significant elevations of plasma triglycerides occur. In most patients, such triglyceride elevations return toward normal within a few days to weeks but occasionally persist.15 As noted above, this probably reflects the increased hepatic synthesis of plasma triglycerides and increased input into plasma of VLDL. In general, I do not attempt to treat this hypertriglyceridemia.
Although many patients cannot tolerate a full therapeutic dose, there are few who cannot tolerate at least two or three scoops per day. For many individuals, even two scoops per day, taken at supper, can be quite effective and lead to significant LDL lowering. This is particularly true in older individuals, in whom the bile acid pool size may be much smaller. In my experience, doses as small as two scoops per day at supper can produce LDL lowering of 30-50% in such individuals. Furthermore, even in patients who cannot tolerate a maximal dose, the use of small doses of a bile resin is worthwhile because these act synergistically with other hypolipidemic agents and when used in combination, can lead to decreased intake of the other agent.
Nicotinic Acid
Nicotinic acid (niacin) effectively lowers elevated levels of both VLDL and LDL. Although it is frequently used as an effective second drug in combination with a bile resin, it has also been used as primary therapy for elevated LDL levels. At the large doses used to treat hypercholesterolemia (2-7 g/day), it probably has the effect of decreasing the output of VLDL from the liver, thus decreasing VLDL levels primarily and LDL levels secondarily. This could occur in part at least initially because of inhibition of the release of fatty acids from adipose tissue and, thus, could deprive the liver of additional substrate for the synthesis of lipoprotein lipid.
Nicotinic acid (niacin) is available in multiple dose forms and in sustained release forms. Nicotinamide, which does not cause flushing, cannot be substituted for nicotinic acid; although it is effective as a vitamin, it has no effect on hyperlipidemia. The usual total dose required to achieve hypolipidemic action is from 2-7 g/day. Side effects are common, and many patients are not able to take the large doses required to make this therapeutically effective. Cutaneous flushing, the most common side effect, occurs even after the ingestion of small doses, but tachyphlaxis to this phenomenon frequently occurs within 2 weeks. It is probably mediated by prostaglandins and can be mitigated in part by aspirin use. I usually instruct patients to take one (or more) aspirin tablets ½/2 hour earlier if this is a problem. Taking the medication with a meal also appears to decrease flushing, and some patients have reported that eliminating coffee from their diet helps further. I usually instruct patients to start with one 100-mg tablet three times a day, taken with meals to decrease gastric irritation. The dose is then gradually increased at weekly intervals while carefully monitoring side effects and liver function. I prefer to use 100-mg tablets (or half of a 250-mg tablet) because of increased reliability and predictability of absorption. In some patients on large doses, 250or 500-mg tablets may be substituted. Although other investigators have reported that sustained release forms of nicotinic acid produce less flushing, gastrointestinal side effects may be worse and the overall cholesterol lowering less effective. There are numerous over-the-counter preparations of sustained-release niacin available, but there are essentially no controlled studies of their efficacy or toxicity. The flushing can usually be tolerated by most patients, and although tachyphylaxis to this phenomenon frequently occurs, the flushing episodes can reoccur if patients miss two or three doses. With larger doses, elevations of hepatic transaminases are common but usually are reversible with decreased doses. Gradually increasing the dose of nicotinic acid appears to minimize such transaminase elevations. Hyperuricemia commonly occurs, and a history of symptomatic gout is a definite contraindication. Similarly, a history of peptic ulcer disease is also a contraindication. Fasting hyperglycemia is also an occasional side effect.
Although many experts use nicotinic acid as a first-line drug, because of its many side effects I use it most commonly in combination with a bile sequestrant, particularly in young patients, or more recently in combination with a bile sequestrant and lovastatin for selected severely hypercholesterolemic patients.
An important potential benefit of nicotinic acid is its consistent effect in increasing HDL cholesterol levels. Such an effect theoretically provides an additional benefit of therapy. In fact, among all hypolipidemic drugs, it is the only one that has been associated with a significant decrease in secondary coronary events and in a long-term decrease in total mortality.39 Many patients with a history of CAD have low HDL cholesterol levels as their primary lipoprotein disorder. The use of nicotinic acid may be appropriate therapy for such individuals, but evidence to support this view is lacking. Probucol
Probucol is a highly lipophilic drug, introduced as a hypolipidemic agent, that has subsequently been shown by our group to be a potent antioxidant.29 On average, it lowers LDL cholesterol levels only 10-20%,25 but responses to this agent vary greatly, and many subjects have little or no LDL response at all. In almost all patients, probucol lowers HDL cholesterol levels, and for this reason, the medication has been regarded with caution by many investigators. Nevertheless, because only probucol, reported to be effective in subjects with homozygous FH, interest in its use is high. In such subjects, probucol has been reported to lower LDL levels modestly and, more important, to cause dramatic reductions in xanthomas. In fact, Japanese investigators have reported that the reduction in size of xanthomas correlates best with the reduction in HDL cholesterol levels. 40 The latter observation points to our lack of knowledge about the physiologic implications of changes in HDL levels.
The mechanism by which probucol lowers LDL levels is uncertain. The fact that it can lower LDL levels in subjects completely lacking LDL receptors implies that it must work by a non-LDL receptormediated mechanism. Furthermore, because it is highly lipophilic, it is taken up and transported in the lipoproteins themselves, principally in LDL in patients with hypercholesterolemia. Incorporation of probucol into LDL is likely to alter it in such a way that its recognition by cell surfaces or receptors is also altered. In patients treated with probucol, LDL appears to be cleared from plasma at an enhanced rate, but it is not clear whether this effect is related to changes in the structure of LDL that were noted in rabbit studies. 41 As noted above, probucol decreases plasma LDL levels in subjects with homozygous FH and produces an associated decrease in planar and tendon xanthomas. Significant reductions in HDL occur at the same time. Clinical studies are currently ongoing that could help clarify its use as an antiatherogenic medication. At present, I consider probucol a secondary drug for the treatment of hypercholesterolemia and usually use it only in association with other medications. Because its mode of action appears to be different from that of the other commonly used hypolipidemic agents, it should theoretically be of benefit when used in combination with other drugs, such as bile sequestrants. In fact, several studies have reported that probucol will produce a further lowering of LDL levels in patients already on a bile sequestering agent, but again, the response is variable.38,42,43 Recent data from our laboratory clearly document that, for the vast majority of patients, it does not add any further cholesterol lowering when added to a subject already on lovastatin. 25 Finally, as noted earlier, probucol is a potent antioxidant agent. Because it is highly lipophilic, it is carried exclusively in the core of lipoproteins, chiefly in LDL. Much evidence has been accumulated by our group, and others, that oxidative modification of LDL enhances its atherogenicity. 28 The presence of oxidized LDL has been shown in rabbit and human aortic lesions.44'45 LDL isolated from patients on conventional doses of probucol is resistant to oxidative modification in vitro. 29 Carew et a130 and Kita et a146 have also shown that probucol treatment of spontaneously hypercholesterolemic rabbits will retard the progression of their atherosclerosis, independent of probucol's ability among all known hypolipidemic agents, has been to lower LDL cholesterol levels. Furthermore, Carew and colleagues showed that probucol specifically inhibited the degradation of LDL within macrophage-rich lesions of the aorta, which is consistent with its antioxidant properties. Obviously, much work remains to be performed before this concept can be applied to humans, but the idea that antioxidant therapy can prevent modification of LDL and thereby inhibit atherogenesis deserves further experimentation.
The current recommended dosage of probucol is 500 mg twice daily. It is associated with few side effects, although occasional patients will complain of gastrointestinal symptoms and headaches. Electrocardiographic monitoring has revealed a mild prolongation of the QT interval in some individuals, although no adverse clinical consequences have been reported in humans.
HMG CoA Reductase Inhibitors
Development of specific competitive inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, HMG CoA reductase, has provided a giant step forward in the ability to successfully treat patients with moderate-to-severe hypercholesterolemia. Lovastatin (formerly known as mevinolin) is currently available in the United States, and well over a million patients are taking this medication. Sinvastatin (synvinolin or MK733) and pravastatin (CS514) are currently undergoing clinical trials in North America and Europe and should shortly be available. These drugs act both by inhibiting cholesterol synthesis, resulting in inhibition of the production of lipoproteins, and by induction of hepatic LDL receptor activity, which leads to enhanced removal of LDL particles and their precursors as explained above. In my opinion, these drugs have revolutionized the therapy of hypercholesterolemia and appear to be the most efficacious and best tolerated drugs to date. An excellent, comprehensive review of these agents has recently been published. 47 Lovastatin, as the prototype of this class of drugs, is prescribed at dosages of 20-80 mg/day. At dosages of 40-80 mg/day, it produces LDL lowering of 35-45% in subjects with FH and non-FH. In addition, triglyceride levels are lowered modestly, 15-20%, and HDL cholesterol levels actually increase in the order of 5-10%. Most important, nearly all patients respond to lovastatin. Lovastatin is easy to administer and patients' acceptance and compliance are outstanding. Most studies have shown that minor side effects are no greater than side effects in placebotreated controls. Approximately 2-3% of patients will develop minor elevations in hepatic transaminase functions, but in my experience, nearly all of these patients are concurrently consuming alcohol. In most individuals, discontinuation (or reduction) of alcohol intake has led to normalization of the transaminase elevations, even as lovastatin therapy is continued. A rare but most troubling side effect is myositis, which may present as diffuse or specific muscular pain, associated with an elevated creatine phosphokinase level. 47 Rarely, patients taking lovastatin in combination with nicotinic acid, or gemfibrozil, have had severe myositis with rhabdomyolysis and even acute renal failure. Fortunately, this situation is rare, and to date, all reported cases have rapidly reversed and subsequently returned to normal with discontinuation of the lovastatin. Lovastatin administration to patients after cardiac transplantation, who are receiving cyclosporin and other immunosuppressive drugs, has been associated with a high incidence of this syndrome, estimated to be as high as one third of these selected patients.47 Lovastatin was found to produce cataracts in dogs, but the accumulating data suggest that this is very unlikely to be a problem in humans. Thus, the only remaining concern is that of potential long-term complications, which of course cannot really be ascertained until the drug has been used for many years. This is not a minor consideration because by its very nature, primary prevention of atherosclerosis by treatment of hypercholesterolemia implies long-term administration. Consequently, this unknown risk must be taken into account whenever this class of drugs is prescribed. This will be discussed further in the section below.
Gemfibrozil
Several drug analogs of clofibrate have been developed that have hypolipidemic action. Fenofibrate, bezafibrate, and ciprofibrate are used in several European countries, but only clofibrate and gemfibrozil are available in the United States. In general, these drugs appear to affect multiple sites in the lipoprotein pathway. Clinically, they appear to inhibit VLDL production and enhance VLDL clearance due to stimulation of lipoprotein lipase activity. Gemfibrozil causes a decrease of 20-30% in plasma triglyceride levels and concurrently an increase of 10-20% in HDL cholesterol levels. Its effect on LDL levels is less marked and more variable, and it is not used as a first-line drug to lower LDL levels. In fact, for many patients, LDL levels can actually rise as triglyceride levels (VLDL) decrease. Bezafibrate, ciprofibrate, and fenofibrate might be more effective in lowering LDL levels (reviewed in Reference 48), but in general, even these drugs are not as effective as the other primary drugs used to lower LDL levels.
Gemfibrozil, which is the agent in this class most commonly used in the United States, is generally well tolerated. A related drug, clofibrate, significantly increased the risk for cholelithiosis. Gemfibrozil, while also lithogenic, appears to be safer in this regard because no increased incidence of gallstones was seen in the Helsinki Heart Study,35 but long-term follow-up is still needed. It potentiates the actions of coumadin and might induce a myositis syndrome, particularly when combined with lovastatin. I use this agent primarily in the treatment of patients with combined hypertriglyceridemia and hypercholesterolemia, particularly when associated with low HDL levels. Usually such patients have familial combined hyperlipidemia or a strong family history of CAD (see below). It is also very effective in patients with type III hyperlipoproteinemia and in those who have the type V hyperlipoproteinemia phenotype.49
Approach to Drug Treatment of Hypercholesterolemia It should go without saying that all patients with hypercholesterolemia should be given a modified diet as the initial form of therapy. Diet prescriptions include limitation of total fat to 20-30% of calories, with equal parts of monounsaturated, polyunsaturated, and saturated fats and restriction of dietary cholesterol to less than 200 mg/day (reviewed in References 50 and 51). Ideally, all patients should see a dietitian to review their dietary habits and to optimize chances for maximal dietary effect. In general, subjects with mild elevations of total plasma cholesterol (i.e., 200-250 mg/dl) will have the best response to dietary changes. Patients with more severe elevations and those with heterozygous FH are more resistant. Nevertheless, with strict and persistent dietary restrictions, even FH patients can have decreases in total plasma cholesterol of up to 20%.51 For all patients, a minimum of 3-6 months of strict dietary control should be tried before drug therapy is considered. For subjects in whom LDL levels remain above the desired level despite diet, drug therapy is then instituted in a stepped-care approach.
My initial approach is to use a bile resin in nearly all patients. Because hypolipidemic therapy implies a long-term commitment, possibly for a lifetime, the long-term issue of safety is of paramount importance. Bile resins are nonsystemic and have a 20-year history of safety under close scrutiny. Most patients can tolerate some resin therapy, that is, two scoops at supper, whereas for many patients larger doses may be poorly tolerated. For many patients, particularly older individuals or those with modest degrees of hypercholesterolemia, this may be sufficient to produce significant cholesterol lowering. Even for those individuals in whom the desired therapeutic goal has not been achieved, the doses of resin taken may reduce the amount of the second agent that needs to be taken, thereby reducing both the risk and the overall expense. In the past, when a second agent was required, nicotinic acid was my first choice, but with the widespread use of lovastatin and its apparent safety, at least for the short-term, I have increasingly prescribed lovastatin as the second agent. As described above, it is extremely well tolerated and extraordinarily effective. For individuals already on a bile resin, I start with 20 mg at supper and gradually increase the dose to achieve the desired result. For many indi-viduals, two packets of resin therapy and one 20-mg tablet of lovastatin at supper will produce the desired goal. For individuals with heterozygous FH, it is commonly necessary to prescribe fairly large dosages, up to 80 mg/day, which is currently the maximal allowed dosage. On average, the combination of a bile resin and lovastatin 40 mg/day will produce LDL cholesterol lowering of 50-55%, even in patients with severe heterozygous FH (Figure 4) . Note that all patients responded to this regimen, with a minimum reduction of 40% and a maximum reduction of 70%. In young patients with heterozygous FH, I still try to use the combination of a bile resin and nicotinic acid first because their exposure to medication will be the longest, and this combination can produce comparable results.18 Finally, in the unusual patient in whom LDL levels still remain above the desirable level while receiving a combination of a bile resin and lovastatin, nicotinic acid can be added but only with great caution. As shown by Malloy et al,26 these three drugs in combination produced an average lowering of LDL of 67% in subjects with FH. The efficacy of this therapy is illustrated by our recent experience with an FH heterozygote who had undergone CABG surgery at age 51 years. Initial total cholesterol and LDL cholesterol levels were 325 and 242 mg/dl, respectively. In response to cholestyramine and lovastatin, LDL cholesterol was lowered 66%. Nicotinic acid was then added to the therapeutic regimen and was gradually increased to 4 g/day, at which time total cholesterol levels fell to 87 mg/dl with an LDL of 37 mg/dl, clearly an effective response! However, at this time, mild transaminase elevations were noted, and the dose of nicotinic acid was then reduced.
To date, our practice has been to limit the use of probucol to a second-line agent to be used only when lovastatin or nicotinic acid cannot be used, or possibly in combination with a bile resin and lovastatin, in those individuals who cannot tolerate nicotinic acid. As noted above, the use of probucol as an antioxidant to prevent atherosclerosis in humans lacks any data and must await further clinical trials. However, for the high-risk patient, its use as adjunctive therapy could be considered on an individual basis.
Not infrequently, patients are seen in whom elevations of LDL are associated with elevations of VLDL, either concurrently or alternatively. Such patients, with presumed combined hyperlipidemia, present unique challenges. The traditional therapy for such patients has been to begin with the triglyceride-lowering agent, gemfibrozil, which is effective in lowering VLDL levels (and hence triglyceride levels). However, quite commonly, this also results in a significant elevation in LDL levels. In our experience, addition of a bile resin will usually not reduce the elevated LDL levels. Recent experience with lovastatin in combination with gemfibrozil has produced rather dramatic reductions in FIGURE 4. Plot of maximal response of total and low-density lipoprotein cholesterol during intensive combination hypolipidemic therapy. Seventeenpatients with heterozygous FH were treated with varying combinations of lovastatin, colestipol, and probucol. The optimal cholesterol lowering, usually achieved with lovastatin and colestipol, is shown. Note that all patients responded with a minimal decrease of 40% and a maximal response of 70% (reproduced with pernission from Reference 25).
both VLDL and LDL levels. In fact, use of lovastatin alone for patients with familial combined hyperlipidemia can be quite effective in reducing VLDL and LDL levels. My recent practice has been to initiate therapy with lovastatin alone for such patients and then to use gemfibrozil as a second agent as necessary to further reduce elevated VLDL levels. 52 Again, attention is directed to the observation that the combined use of lovastatin and gemfibrozil has been associated with an increased incidence of myositis, although in my experience, this still remains a rare event.
Cost of Medications
Currently, a major drawback to effective treatment of hypercholesterolemia is the high cost of medications. Table 3 shows prices for these agents. Bile resins should always be prescribed in bulk form, which is considerably cheaper. Nicotinic acid is an extremely inexpensive form of therapy, and I prescribe generic forms that can be bought over the counter in nearly all drugstores and health food stores. In patients for whom cost is a primary concern, this may be a logical choice for primary therapy. The high cost of medication, particularly of lovastatin, emphasizes the rationale for combined therapy that can reduce the overall need for large doses. It is hoped that the cost of these medications will be reduced as their widespread use occurs and as new agents come on the market. Summary CAD is a complex disease with multiple etiologies and aggravating events. Yet, elevated plasma cholesterol levels, chiefly in the form of LDL, are essential for the progression of the atherosclerotic lesion. Any total plasma cholesterol level above an ideal of 180 mg/dl (and an LDL cholesterol level of 100 mg/dl) must be considered atherogenic in the presence of other risk factors. In patients at high risk for death from CAD, combined diet and drug therapy should have as a goal the attainment of ideal lipoprotein values. Drug therapies are now available that make it possible to substantially lower elevated LDL levels in almost all patients and even to achieve ideal levels in those at highest risk. 
